SCM
PCRX icon

Stevens Capital Management’s Pacira BioSciences PCRX Stock Holding History

Stevens Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,112
Closed -$220K – 1158
2015
Q2 		$220K Buy
+3,112
New +$245K 0.01% 846

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stevens Capital Management's PCRX Position: Q3 2015 in Review

Stevens Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2015, closing a stake of 3,112 shares — an estimated $220K sold.

Stevens Capital Management first reported a position in PCRX in Q2 2015 and held it in 1 quarter. The position peaked at $220K in Q2 2015. 177 funds tracked by Wall St. Rank hold PCRX as of Q3 2015.

  • Stevens Capital Management reported no remaining Pacira BioSciences position as of Q3 2015 after selling out during the quarter.
  • Stevens Capital Management sold 3,112 Pacira BioSciences shares in Q3 2015, an estimated $220K.
  • Stevens Capital Management first reported a position in Pacira BioSciences in Q2 2015 and held it in 1 quarter.
  • Stevens Capital Management's Pacira BioSciences position peaked at $220K in Q2 2015.
  • 177 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2015.

Based on Stevens Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.